COMPLETION OF FIRST TRANCHE

Source: RNS
RNS Number : 5547G
Reckitt Benckiser Group PLC
02 October 2024
 

RECKITT BENCKISER GROUP PLC

 

2024 SHARE BUYBACK PROGRAMME

COMPLETION OF FIRST TRANCHE AND COMMENCEMENT OF SECOND TRANCHE

 

 

Reckitt Benckiser Group plc ("Reckitt" or the "Company") confirms the successful completion of the first tranche of £250m (the "First Tranche") of its 2024 £1 billion share buyback programme (the "Programme") announced on 24 July 2024.

 

Under the First Tranche, between 26 July 2024 and 1 October 2024, the Company has purchased 5,655,355 ordinary shares of 10p each (the "Ordinary Shares") at an average price of £44.21, and which are now held in treasury.

 

Further to the announcement on 24 September 2024, the Company confirms that the second tranche of the Programme (the "Second Tranche") to return a further up to £250 million of capital to shareholders, will commence on 2 October 2024 and will end on or before 20 December 2024.  As previously announced, the purpose of the Second Tranche is to reduce the share capital of the Company. The Second Tranche will take place within the limitations of the authority granted to the Board by shareholders at the Company's Annual General Meeting on 2 May 2024. Pursuant to that authority, the maximum number of shares which remain available for purchase under the Second Tranche is 56,500,000.

 

As previously announced, Reckitt has entered into an agreement with Numis Securities Limited ("DN") under which it has instructed DN to manage the Second Tranche of the Programme.  DN will, acting as riskless principal, purchase Ordinary Shares for an aggregate purchase price of no greater than £250 million and will simultaneously sell such Ordinary Shares on to the Company. To the extent permitted by law, Ordinary Shares purchased under the Second Tranche of the Programme will be held in treasury.

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

 

CONTACT DETAILS:

 

Richard Joyce                                                    +44 (0)7807 418516

Investor Relations

 

Catheryn O'Rourke                                             +44 (0) 1753 217 800

General Counsel & Company Secretary

 

About Reckitt:

 

Reckitt* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege.

 

Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Calgon, Cillit Bang, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more.

 

Every day, more than 20 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always.

 

We are a diverse global team of c. 40,000 colleagues. We draw on our collective energy to meet our ambitions of purpose-led brands, a healthier planet and a fairer society.  Find out more, or get in touch with us at www.reckitt.com

 

* Reckitt is the trading name of the Reckitt Benckiser group of companies

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPGGUUUPCPUG